Summary
However, there are several tools and solutions for aiding the melanoma detection (variable dermatoscopes, full-body mapping tools and Applications), they were not able to achieve breakthrough in the early diagnosis phase. It comes from the wrong methodologies. There are two types of available tools: 1) diagnostic tools, whit the aim of diagnosing skin-cancer without human intervention, and 2) medical equipment, which help the work of dermatologist during the examination in a doctor’s office. The problem with first methodology (artificial based skin-cancer diagnosis) is that these do not work reliable or do not work at all. The main problem of the second methodology is the very rare examination frequency. An average health conscious European adult visits skin-cancer screening in every 3-7 years.
In contrast with these, MERWIS offers a solution that focuses on increasing the examination frequency, where the system does not need to establish a full diagnosis. MERWIS only looks for evolution (change) of every single monitored mole, but with high or very high frequency.
The validated and demonstrated MERWIS prototype is based on the fact that most clinical signs of melanoma are all visible. Through using the combination of a special body-mapping cabin, a mobile application based “self dermoscopy”, and a computer assisted qualitative data analysis software we can detect all the visible changes of melanoma ABCDE. Furthermore our system uses a custom made distributed ledger technology-based network cloud solution. Based on this framework it is possible to build the MERWIS decentralized database on a maximum security level and ensure scalability.
The aim of this Phase 1 project is to carry out an extended feasibility study consisting of market assessment, business model validation, risk and IP strategy assessment, up-date and advancement of the business plan, and international pilot location selection to support the global commercialisation of our technology.
In contrast with these, MERWIS offers a solution that focuses on increasing the examination frequency, where the system does not need to establish a full diagnosis. MERWIS only looks for evolution (change) of every single monitored mole, but with high or very high frequency.
The validated and demonstrated MERWIS prototype is based on the fact that most clinical signs of melanoma are all visible. Through using the combination of a special body-mapping cabin, a mobile application based “self dermoscopy”, and a computer assisted qualitative data analysis software we can detect all the visible changes of melanoma ABCDE. Furthermore our system uses a custom made distributed ledger technology-based network cloud solution. Based on this framework it is possible to build the MERWIS decentralized database on a maximum security level and ensure scalability.
The aim of this Phase 1 project is to carry out an extended feasibility study consisting of market assessment, business model validation, risk and IP strategy assessment, up-date and advancement of the business plan, and international pilot location selection to support the global commercialisation of our technology.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/878237 |
| Start date: | 01-08-2019 |
| End date: | 31-12-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
However, there are several tools and solutions for aiding the melanoma detection (variable dermatoscopes, full-body mapping tools and Applications), they were not able to achieve breakthrough in the early diagnosis phase. It comes from the wrong methodologies. There are two types of available tools: 1) diagnostic tools, whit the aim of diagnosing skin-cancer without human intervention, and 2) medical equipment, which help the work of dermatologist during the examination in a doctor’s office. The problem with first methodology (artificial based skin-cancer diagnosis) is that these do not work reliable or do not work at all. The main problem of the second methodology is the very rare examination frequency. An average health conscious European adult visits skin-cancer screening in every 3-7 years.In contrast with these, MERWIS offers a solution that focuses on increasing the examination frequency, where the system does not need to establish a full diagnosis. MERWIS only looks for evolution (change) of every single monitored mole, but with high or very high frequency.
The validated and demonstrated MERWIS prototype is based on the fact that most clinical signs of melanoma are all visible. Through using the combination of a special body-mapping cabin, a mobile application based “self dermoscopy”, and a computer assisted qualitative data analysis software we can detect all the visible changes of melanoma ABCDE. Furthermore our system uses a custom made distributed ledger technology-based network cloud solution. Based on this framework it is possible to build the MERWIS decentralized database on a maximum security level and ensure scalability.
The aim of this Phase 1 project is to carry out an extended feasibility study consisting of market assessment, business model validation, risk and IP strategy assessment, up-date and advancement of the business plan, and international pilot location selection to support the global commercialisation of our technology.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
